
Gastric cancer (GC) remains a significant global health challenge, ranking as the fifth most common cancer and the third leading cause of cancer-related deaths worldwide. Despite declining incidence rates in certain regions, such as the United States, mortality remains high, particularly in Eastern Asia. In this review, we explore innovative immunotherapeutic strategies for GC, including immune checkpoint inhibitors, CAR-T cell therapy, and therapeutic vaccines. The role of the tumor microenvironment (TME), immune cell interactions, tumor acidity, and microbial flora in shaping therapeutic responses is discussed. Emerging epidemiological trends, such as the rise of cardia gastric cancer and shifts in traditional risk factor profiles, underscore the need for targeted prevention strategies. While immunotherapy offers promising opportunities, challenges like therapeutic resistance and personalization of treatment persist. We aimed to highlight advancements in GC immunotherapy to promote research and improve patient outcomes.
Citation: Mujibullah Sheikh, Pranita S. Jirvankar. Innovative immunotherapeutic strategies for gastric cancer: A comprehensive review[J]. AIMS Allergy and Immunology, 2025, 9(1): 27-55. doi: 10.3934/Allergy.2025003
[1] | Cheng-Cheng Zhu, Jiang Zhu . Spread trend of COVID-19 epidemic outbreak in China: using exponential attractor method in a spatial heterogeneous SEIQR model. Mathematical Biosciences and Engineering, 2020, 17(4): 3062-3087. doi: 10.3934/mbe.2020174 |
[2] | Yongli Cai, Yun Kang, Weiming Wang . Global stability of the steady states of an epidemic model incorporating intervention strategies. Mathematical Biosciences and Engineering, 2017, 14(5&6): 1071-1089. doi: 10.3934/mbe.2017056 |
[3] | Danfeng Pang, Yanni Xiao . The SIS model with diffusion of virus in the environment. Mathematical Biosciences and Engineering, 2019, 16(4): 2852-2874. doi: 10.3934/mbe.2019141 |
[4] | Pengfei Liu, Yantao Luo, Zhidong Teng . Role of media coverage in a SVEIR-I epidemic model with nonlinear incidence and spatial heterogeneous environment. Mathematical Biosciences and Engineering, 2023, 20(9): 15641-15671. doi: 10.3934/mbe.2023698 |
[5] | Azmy S. Ackleh, Keng Deng, Yixiang Wu . Competitive exclusion and coexistence in a two-strain pathogen model with diffusion. Mathematical Biosciences and Engineering, 2016, 13(1): 1-18. doi: 10.3934/mbe.2016.13.1 |
[6] | Youshan Tao, J. Ignacio Tello . Nonlinear stability of a heterogeneous state in a PDE-ODE model for acid-mediated tumor invasion. Mathematical Biosciences and Engineering, 2016, 13(1): 193-207. doi: 10.3934/mbe.2016.13.193 |
[7] | Wenzhang Huang, Maoan Han, Kaiyu Liu . Dynamics of an SIS reaction-diffusion epidemic model for disease transmission. Mathematical Biosciences and Engineering, 2010, 7(1): 51-66. doi: 10.3934/mbe.2010.7.51 |
[8] | Nalin Fonseka, Jerome Goddard Ⅱ, Alketa Henderson, Dustin Nichols, Ratnasingham Shivaji . Modeling effects of matrix heterogeneity on population persistence at the patch-level. Mathematical Biosciences and Engineering, 2022, 19(12): 13675-13709. doi: 10.3934/mbe.2022638 |
[9] | Liqiong Pu, Zhigui Lin . A diffusive SIS epidemic model in a heterogeneous and periodically evolvingenvironment. Mathematical Biosciences and Engineering, 2019, 16(4): 3094-3110. doi: 10.3934/mbe.2019153 |
[10] | Shuangshuang Yin, Jianhong Wu, Pengfei Song . Analysis of a heterogeneous SEIRS patch model with asymmetric mobility kernel. Mathematical Biosciences and Engineering, 2023, 20(7): 13434-13456. doi: 10.3934/mbe.2023599 |
Gastric cancer (GC) remains a significant global health challenge, ranking as the fifth most common cancer and the third leading cause of cancer-related deaths worldwide. Despite declining incidence rates in certain regions, such as the United States, mortality remains high, particularly in Eastern Asia. In this review, we explore innovative immunotherapeutic strategies for GC, including immune checkpoint inhibitors, CAR-T cell therapy, and therapeutic vaccines. The role of the tumor microenvironment (TME), immune cell interactions, tumor acidity, and microbial flora in shaping therapeutic responses is discussed. Emerging epidemiological trends, such as the rise of cardia gastric cancer and shifts in traditional risk factor profiles, underscore the need for targeted prevention strategies. While immunotherapy offers promising opportunities, challenges like therapeutic resistance and personalization of treatment persist. We aimed to highlight advancements in GC immunotherapy to promote research and improve patient outcomes.
Gastric cancer;
Gastrointestinal stromal tumors;
Mortality-to-incidence ratio;
Carcinoma-associated fibroblasts;
Immune checkpoint inhibitors;
Tumor microenvironment;
Tumor-associated macrophages;
Myeloid-derived suppressor cells;
Colony-stimulating factor 1 receptor;
programmed cell death protein 1;
programmed cell death ligand 1;
Triple-negative breast cancer;
Hepatocellular carcinoma;
Renal cell carcinoma;
Endometrial cancer
The idea of invisible living creatures as agents of disease goes back at least to the writings of Aristotle (384 BC–322 BC). In the 16th century, it developed as a theory. The AIDS epidemic, the recent SARS epidemic, MERS, Ebola virus and outbursts of diseases such as the Zika virus are events of concern and interest to many people. The mechanism of transmission of infections is now known for most diseases. Some diseases transmitted by viral agents, such as influenza, measles, rubella and chicken pox, confer immunity against reinfection, others transmitted by bacteria, such as tuberculosis, meningitis, and gonorrhea, confer no immunity against reinfection. While malaria, is transmitted not directly from human to human but by vectors, usually insects that are infected by humans transmit the disease to humans. There are also diseases such as West Nile virus which are transmitted back and forth between animals and vectors [1]. The first known result in mathematical epidemiology is a defense of the practice of inoculation against smallpox in 1760 by Daniel Bernouilli. The first contributions to modern mathematical epidemiology are due to P.D. En'ko between 1873 and 1894 [2], then many scholars pay more attention to the global stability problem [3,4,5,6,7], bifurcation problem [8,9,10,11] and the optimal control problem [12,13] of the disease.
Recently, reaction–diffusion equations have been used by many authors in epidemiology as well as virology. Researchers have established many types of model with diffusion such as SIR model [14,15], SIS model [16], Lyme disease model [17,18], malaria model [19] and so on. Some authors specifically study the global stability of the spread of diseases [20,21,22,23,24,25,26,27]; others discuss the traveling wave solutions about reaction–diffusion models [28,29,30,31,32,33]. The authors of [34] applied energy estimates in their proofs to discussed cholera epidemic.
In the theory of epidemiology, it has been recognized that environmental heterogeneity is a significant factor in the spread of infectious diseases. Constrained by factors such as altitude, temperature, humidity, latitude, climate, and living factors, the diffusion of epidemics in different environments is vastly different. In 2008, Allen et al. [35] proposed a simple diffusive SIS (susceptible–infected–susceptible) model with space-dependent disease transmission rate β(x) and recovery rate γ(x), given by
{∂S∂t=dSΔS−β(x)SIS+I+γ(x)I, x∈Ω,t>0,∂I∂t=dIΔI+β(x)SIS+I−γ(x)I, x∈Ω,t>0,∂S∂n=∂I∂n=0, x∈∂Ω,t>0,S(x,0)=S0(x),I(x,0)=I0(x), x∈Ω. | (1.1) |
where Ω is a bounded domain in Rm and S+I is the total number of individuals at t=0. They studied the existence, uniqueness, stability of the disease-free equilibrium and studied the asymptotic behavior of the unique endemic equilibrium as dS approaches zero. More precisely, their results implied that if the spatial environment can be modified to include low-risk sites and the movement of susceptible individuals can be restricted, then it may be possible to eliminate the infectious disease. In some subsequent work, Peng [36] discussed the asymptotic profiles of the steady states for the epidemic reaction–diffusion model (1.1). The global stability of the steady states of (1.1) was also investigated by Peng and Liu [37] in 2009. Four years later, Peng and Yi [38] studied the effects of epidemic risk and population movement on the spatiotemporal transmission of infectious disease via the SIS epidemic reaction–diffusion model (1.1). In 2011, Lou and Zhao [19] introduced a reaction–diffusion malaria model with incubation period in the vector population. Kuniya and Wang [39] gave the Lyapunov functions and global stability for a spatially diffusive SIR epidemic model for only one diffusion, for systems with multiple diffusions, the author did not get the method to construct the Lyapunov function. Deng and Wu [40] discussed the global dynamics of a SIS epidemic reaction-diffusion model, which reads as follows:
{∂S∂t=dSΔS−β(x)SI+γ(x)I, x∈Ω,t>0,∂I∂t=dIΔI+β(x)SI−γ(x)I, x∈Ω,t>0,∂S∂n=∂I∂n=0, x∈∂Ω,t>0,S(x,0)=S0(x),I(x,0)=I0(x), x∈Ω. | (1.2) |
The authors only discussed the attractivity and global stability of the constant coefficient model, and constructed the Lyapunov function of the constant system. Wu and Zou [41] analyzed the asymptotic profiles of steady states for the model (1.2) with mass action infection mechanism. In 2017, Li et al. [42] studied the following SIS reaction-diffusion system with a linear external source:
{∂S∂t−dSΔS=Λ(x)−S−β(x)SIS+I+θγ(x)I, x∈Ω,t>0,∂I∂t−dIΔI=β(x)SIS+I−γ(x)I, x∈Ω,t>0,∂S∂n=∂I∂n=0, x∈∂Ω,t>0,S(x,0)=S0(x),I(x,0)=I0(x), x∈Ω. | (1.3) |
The authors showed the uniform bounds of solutions, established the threshold dynamics in terms of the basic reproduction number and discussed the global stability of the unique constant endemic equilibrium when spatial environment is homogeneous. In particular, the asymptotic profile of endemic equilibria is determined if the diffusion rate of the susceptible or infected population at 0 or ∞. Since the Lyapunov function is difficult to construct, the authors did not discuss the global stability of endemic for heterogeneous models. In 2018, Cai et al. [43] investigated the dynamical outcomes of a host–parasite model incorporating both horizontal and vertical transmissions in a spatial heterogeneous environment. The work of Tong and Lei [44] concerns an SIS epidemic reaction–diffusion model. They also failed to construct Lyapunov functions suitable for spatial heterogeneous models. Therefore, the construction of the Lyapunov function of the spatial heterogeneous model is very difficult. In discussing the long-term dynamic behavior of disease in space, we also need to try to find other methods.
On the other hand, many diseases such as hepatitis, malaria, rabies, tuberculosis and HIV/AIDS will produce relapse after being treatment. We also know that vaccination is an important means of preventing infection and relapse of these diseases. Therefore, the effect of spatial factors on relapse and vaccination should be taken into account. Inspired by the above literature, in this manuscript, we study an SVIR epidemic reaction-diffusion model with relapse and a varying external source in spatially heterogeneous environment. This model has the following significant differences and difficulties compared to the above models. First, after joining the relapse, the coupling between the equations in the system is stronger. Thus, the method to prove the positivity of the solution in the prior literature can no longer be used in the coupled model. Second, because the coefficients in the model are all spatially heterogeneous and the number of equations increases, so the Lyapunov function method, which proves the global asymptotic stability of the system, is also difficult to achieve due to the increased technical difficulty of construction. For this reason, we turn to discuss the global dynamics of the system by using the attractor theory of infinite dimensional dynamical systems. It is well-known that the global attractor is an important theory to describe the long-term dynamic behavior of dissipative infinite-dimensional dynamical systems [45,46,47,48,49,50,51,52,53,54]. Finally, we conduct a large number of numerical simulations. From the simulation we can see that spatial heterogeneity has a great influence on the long-term dynamic behavior of epidemics. Reducing the relapse rate and increasing the vaccination rate can effectively control the spread of the disease.
The organization of this paper is as follows. In Section 2, we present the model under some assumption. Then by using general comparison principle of the quasi-monotone nonlinear reaction-diffusion system and the comparison principle of parabolic equation, we prove the existence of the positive solutions. We also give the uniform boundedness and the existence of global solutions to our system. In Section 3, we prove the existence theorem of global exponential attract set for our real model and apply this result to discuss the global stability and the persistence of the infection disease. That is, by applying the property of global attractor and gradient flow method, we prove that the non-constant disease-free equilibrium is globally asymptotically stable and the endemic is persisting uniformly under some new threshold conditions. To test the validity of our theoretical results, we choose some specific epidemic disease with some more practical and more definitive official data to simulate the global stability and exponential attraction of the model. The stability and global exponential attractiveness of both constant and non-constant equilibria are simulated in Section 4. In Section 5, we give our conclusions and some discussions.
In this section, we consider a reaction-diffusion SVIR model with relapse and spatially heterogeneous environment. Our model is divided into four compartments, namely the susceptible individuals (S), vaccinated individuals (V), infected individuals (I) and temporary restorers (R). The transfer diagram and parameters description as shown below:
From Figure 1, the following system with the initial-boundary-value conditions is constructed by:
{∂S∂t=dSΔS+Λ(x)−β1(x)SIS+I−[μ(x)+α(x)]S, x∈Ω,t>0,∂V∂t=dVΔV+α(x)S−β2(x)VIV+I−μ(x)V, x∈Ω,t>0,∂I∂t=dIΔI+β1(x)SIS+I+β2(x)VIV+I+ρ(x)R−[μ(x)+η1(x)+ϕ(x)]I, x∈Ω,t>0,∂R∂t=dRΔR+ϕ(x)I−[ρ(x)+μ(x)+η2(x)]R, x∈Ω,t>0,∂S∂n=∂V∂n=∂I∂n=∂R∂n=0, x∈∂Ω,t>0,S(x,0)=S0(x),V(x,0)=V0(x),I(x,0)=I0(x),R(x,0)=R0(x), x∈Ω. | (2.1) |
Here, Ω is a bounded domain in Rm(m≥1) with smooth boundary ∂Ω (when m>1), dS,dV,dI,dR>0 are diffusion coefficients and α(x),β1(x),β2(x),ρ(x),ϕ(x),μ(x),η1(x),η2(x) and Λ(x) are positive Hölder continuous functions on accounting for the rates of vaccination, disease transmission, relapse, recovery, natural death, disease-related death and total recruitment scale respectively. Neumann boundary conditions ∂S∂n=∂V∂n=∂I∂n=∂R∂n=0 denotes that the change rate on the boundary of the region Ω is equal to 0. It is straightforward to verify that SIS+I (VIV+I) is a Lipschitz continuous function of S (V) and I in the open first quadrant. Therefore, we can extend it to the entire first quadrant by defining it to be zero whenever S=0 (V=0) or I=0. Throughout the paper, we assume that the initial value S0(x),V0(x),I0(x) and R0(x) are nonnegative continuous functions on ¯Ω, and the number of infected individuals is positive, i.e., ∫ΩI0(x)dx>0. Specific parameters described in Table 1.
Parameter | Description |
S(x,t) | Density of susceptible individuals at location x and time t. |
V(x,t) | Density of vaccinated individuals at location x and time t. |
I(x,t) | Density of infected individuals at location x and time t. |
R(x,t) | Density of temporary restorers at location x and time t. |
Λ(x) | Total recruitment scale into this homogeneous social mixing community at location x. |
α(x) | Vaccination rate at location x. |
βi(x),i=1,2 | Effective transmission rate (average number of effective interactions per susceptible, vaccination individuals and infected individuals) at location x. |
ρ(x) | Relapse rate at location x. |
ϕ(x) | Per-capita recovery (treatment) rate at location x. |
μ(x) | Natural mortality rate at location x. |
ηi(x),i=1,2 | Disease-related death rate at location x. |
With the development of science and technology and the improvement of medical standards, vaccines play an important role in the prevention and control of disease transmission. So we considered a group of people who were vaccinated with preventive vaccines in the model (2.1). In the model, I denotes the infected person, and R denotes the person who is temporarily recovered by treatment after the infection but may also relapse. These two groups of people carry the disease-causing virus, so we need to consider their disease-induced rates. S denotes a susceptible population, and V denotes an uninfected person who has been vaccinated. They are not ill before they are exposed to pathogenic bacteria or infected people, so we only need to consider the natural mortality of these two types of people. There are many diseases in real life that have such properties, such as hepatitis B, smallpox, etc.,
In the following, we discuss the positivity and boundedness of the solution of system (2.1). In many articles, the positivity, boundedness, and existence of solutions of the model have been discussed, such as models that lose immunity in [55,56,57]. The authors in [55] construct a model of ordinary differential equations, which is naturally less difficult for the proof of positive, boundedness, and existence of solutions. For example, the positive problem of the solution can be easily obtained through contradiction analysis even without using the comparison principle. The model in our manuscript is diffused, and the difficulty of analysis is naturally higher than that of the ODE model. Models in [56] and [57] are diffusion models, and the model of [57] assumes that all diffusion coefficients are equal at the time of construction. In [56], when discussing the existence of the solution of the model (Theorem 2.1 in [56]), the condition that the diffusion coefficients are equal is added. We all know that it is very easy to add the equations in the system when the diffusion coefficients are equal, and then researchers can discuss positivity, boundedness and existence of the solution for this equation about the rate of change of the total population. However, the model diffusion coefficients in our manuscripts are different, we refuse to add any conditions to the diffusion coefficient from beginning to end. Therefore, from the perspective of the diffusion system, our model is more general. These are places where our models and discussion methods differ from other existing results. Firstly, we give an comparison theorem for semilinear parabolic differential equation that we need to use later.
Denote
QT=Ω×(0,T], ST=∂Ω×(0,T],Li≡−n∑j,k=1a(i)jk(x)∂2∂xj∂xk+n∑j=1b(i)j(x)∂∂xj,Biui=ui or Biui=∂ui∂n+bi(x)ui, |
where n is the unit outside normal vector of ∂Ω and bi(x)≥0. The following lemma is similar to the Theorem 4.2.9 in Chinese books [58], but for the convenience of the reader, we give its conclusions and a brief proof.
Lemma 2.1. Let u,v∈C2,1(QT)∩C(¯QT), satisfy
{Liui−fi(x,t,u)≥Livi−fi(x,t,v),(x,t)∈QT,Biui≥Bivi,(x,t)∈ST,ui(x,0)≥vi(x,0),i=1,2,...,m, |
and
∂fi∂uj≥0,i≠j,i,j=1,2,...,m. |
Then
(1) u(x,t)≥v(x,t) in QT.
(2) If there exist (x0,t0)∈QT and μ:0≤μ≤m, such that (u−v)μ(x0,t0)=0, then for any (x,t)∈¯Qt0, there has (u−v)μ(x,t)=0.
Proof. Let w=u−v, then by using differential mean value theorem for multivariate functions
Liui−Livi−[fi(x,t,u)−fi(x,t,v)]=Liwi−[fi(x,t,u1,u2,u3,...,um−1,um)−fi(x,t,v1,u2,u3,...,um−1,um)+fi(x,t,v1,u2,u3,...,um−1,um)−fi(x,t,v1,v2,u3,...,um−1,um)+...+fi(x,t,v1,v2,v3,...,vm−1,um)−fi(x,t,v1,v2,v3,...,vm−1,vm)]=Liwi−m∑j=1∂fi∂uj(x,t,v1,...,vj−1,vj+ξj(uj−vj),vj+1,...,um)(uj−vj)=:Liwi+m∑j=1hijwj≥0, i=1,2,...,m. |
In view of ∂fi∂uj≥0,i≠j,i,j=1,2,...,m, therefore, hij=−∂fi∂uj≤0. If x∈¯Ω, we have w(x,0)≥0 and Biwi|ST≥0,i=1,2,...,m. Then by the strong maximum principle in the form of equation derivatives, we can prove that w(x,t)≥0, that is u(x,t)≥v(x,t) in QT. Finally, if there exist (x0,t0)∈QT and μ:0≤μ≤m, such that wμ(x0,t0)=0, then for any (x,t)∈¯Qt0, there has wμ(x,t)=0, that is (u−v)μ(x,t)=0.
The above lemma can also be derived indirectly from [59,Theorem 7.3.4]. Let X:=L2(Ω) be a Banach space, L1,L2,L3 and L4 be a linear operator on D(L)=(D(L1),D(L2),D(L3),D(L4))⊂X defined by
L1S(x):=dSΔS(x),L2V(x):=dVΔV(x),L3I(x):=dIΔI(x),L4R(x):=dRΔR(x),D(L1):={S∈H2(Ω);∂S∂n=0 on ∂Ω},D(L2):={V∈H2(Ω);∂V∂n=0 on ∂Ω},D(L3):={I∈H2(Ω);∂I∂n=0 on ∂Ω},D(L4):={R∈H2(Ω);∂R∂n=0 on ∂Ω}. |
Then, we can see that L1,L2,L3,L4 are respectively the infinitesimal generator of strongly continuous semigroup {etL1}t≥0,{etL2}t≥0,{etL3}t≥0,{etL4}t≥0 in H2(Ω). Let (H2(Ω))4=H2(Ω)×H2(Ω)×H2(Ω)×H2(Ω) and define L:(H2(Ω))4→(H2(Ω))4,∀u:=(S,V,I,R)∈(H2(Ω))4, then
L(S,V,I,R)(x):=(L1S(x)L2V(x)L3I(x)L4R(x)), D(L):=D(L1)×D(L2)×D(L3)×D(L4) |
is also the infinitesimal generator of a strongly continuous semigroup {etL}t≥0 in Y:=(H2(Ω))4, where
etL=(etL1etL2etL3etL4) and etLu=(etL1SetL2VetL3IetL4R). |
Note that Y is a Banach space equipped with norm
‖(S,V,I,R)T‖Y:=max{‖S‖H2(Ω),‖V‖H2(Ω),‖I‖H2(Ω),‖R‖H2(Ω)}. |
Let G be a nonlinear operator on Y defined by
G(S,V,I,R)(x):=(g1(S,V,I,R)(x),g2(S,V,I,R)(x),g3(S,V,I,R)(x),g4(S,V,I,R)(x))T, |
where
g1(S,V,I,R)(x)=Λ(x)−β1(x)SIS+I−[μ(x)+α(x)]S,g2(S,V,I,R)(x)=α(x)S−β2(x)VIV+I−μ(x)V,g3(S,V,I,R)(x)=β1(x)SIS+I+β2(x)VIV+I+ρ(x)R−[μ(x)+η1(x)+ϕ(x)]I,g4(S,V,I,R)(x)=ϕ(x)I−[ρ(x)+μ(x)+η2(x)]R. |
Let F=(f1,f2,f3,f4), where
fi(S,V,I,R)={gi(S,V,I,R)(x), S,V,I,R>0,0, others, i=1,2,3,4. |
Using the operators L and F defined by above, we can rewrite the problem (2.1) into the following abstract form in Y.
ddtu(t)=Lu(t)+F(u(t)), u(t):=(S(⋅,t)V(⋅,t)I(⋅,t)R(⋅,t)), u(0):=(S0(⋅)V0(⋅)I0(⋅)R0.(⋅)). | (2.2) |
Because L is the generator of a C0-semigroup of contractions on Y and F is locally Lipschitz with respect to u, apply [60,Corollary 11.1.2] and [60,Corollary 11.3.1], we know that there exists at least one saturated solution u:[0,T)→Y, which is a classical solution of system (2.2), such that
u(t)=etLu0+∫t0e(t−s)LF(u(s))ds. | (2.3) |
Moreover, if S(x,0),V(x,0),I(x,0),R(x,0)∈C2(Ω), then u(x,t)∈C2,1(Ω×(0,T]).
In the following, we discuss the positivity of the solution of system (2.2) and the existence of the solution of system (2.1).
Theorem 2.2. Assume that (S(x,t),V(x,t),I(x,t),R(x,t)) be a solution of system (2.2), and S(x,t),V(x,t),I(x,t),R(x,t)∈C(¯Ω×(0,T])∩C2,1(Ω×(0,T]) where T is the maximal existing time. If S(x,0)>0,V(x,0)>0,I(x,0)>0,R(x,0)>0 for x∈Ω, then the solution S(x,t)>0,V(x,t),>0,I(x,t)>0,R(x,t)>0,(x,t)∈Ω×(0,T] and u(t)=(S(x,t),V(x,t),I(x,t),R(x,t)) is a solution ofsystem (2.1).
Proof. We denote that
~f1(S,V,I,R)={−β1(x)SIS+I−[μ(x)+α(x)]S, S,V,I,R>0,0, others, ~f2(S,V,I,R)={−β2(x)VIV+I−μ(x)V, S,V,I,R>0,0, others. |
It is obviously that ~f1(S,V,I,R)≤f1(S,V,I,R) and 0 is a solution of equation
{∂S∂t−dSΔS=~f1(S,V,I,R),∂S∂n=0,S(x,0)=0. |
If S is the solution of the equation
{∂S∂t−dSΔS=f1(S,V,I,R),∂S∂n=0,S(x,0)=S0(x)>0. |
then by using [61,Theorem 2.2.1], we get S(x,t)>0. Similarly, it is obviously that ~f2(S,V,I,R)≤f2(S,V,I,R) and 0 is a solution of equation
{∂V∂t−dVΔV=~f2(S,V,I,R),∂V∂n=0,V(x,0)=0. |
If V is the solution of the equation
{∂V∂t−dVΔV=f2(S,V,I,R),∂V∂n=0,V(x,0)=V0(x)>0. |
then by using [61,Theorem 2.2.1], we get V(x,t)>0. At this time, S and V are just the solutions of the first and the second equations system (2.2). Then for the third and the forth equations of system (2.2), we know that
∂f3∂R={ρ(x), S,V,I,R>0,0, others, ∂f4∂I={ϕ(x), S,V,I,R>0,0, others, |
therefore, ∂f3∂R≥0,∂f4∂I≥0. By the comparison principle Lemma 2.1, we can obtain I(x,t)>0 and R(x,t)>0. Because under the condition of S,V,I,R>0, we have F=G, therefore, u(t) is also the solution of (2.1).
From now on, for any given continuous function f on ¯Ω, we denote
f∗=maxx∈¯Ωf(x) and f∗=minx∈¯Ωf(x). |
In the following, we need to give the Gronwall type differential inequality. Moreover, we do not make assumptions about the positivity of all the functions that appear in the lemma. This lemma will play an important role in the proof of the following lemmas and theorems.
Lemma 2.3. u(t),c(t),h(t) are three real functions defined on [a,T), u(t) is absolutely continuous on [a,T), c(t) is integrable on [a,T). If the following inequality holds,
ddtu(t)+c(t)u(t)≤h(t),a.e.t∈[a,T), | (2.4) |
then
u(t)≤e−∫tac(τ)dτu(a)+∫tae−∫tsc(τ)dτh(s)ds. |
Theorem 2.4. Assume that (S(x,t),V(x,t),I(x,t),R(x,t)) be a solution of system (2.1), and S(x,t),V(x,t),I(x,t),R(x,t)∈C(¯Ω×(0,T])∩C2,1(Ω×(0,T]) where T is the maximal existing time. If S(x,0)>0,V(x,0)>0,I(x,0)>0,R(x,0)>0 for x∈Ω, then the solution (S(x,t),V(x,t),I(x,t),R(x,t)) uniformly bounded on ¯Ω.
Proof. We consider the following total population at time t. Define
U(t)=∫Ω[S(x,t)+V(x,t)+I(x,t)+R(x,t)]dx. |
From system (2.1), it is easy to see that
dU(t)dt=∫Ω[∂∂tS(x,t)+∂∂tV(x,t)+∂∂tI(x,t)+∂∂tR(x,t)]dx=∫Ω{dSΔS+dVΔV+dIΔI+dRΔR+Λ(x)−μ(x)S−μ(x)V−[μ(x)+η1(x)]I−[μ(x)+η2(x)]R}dx≤dS∫ΩΔSdx+dV∫ΩΔVdx+dI∫ΩΔIdx+dR∫ΩΔRdx+∫Ω{Λ∗−μ∗[S+V+I+R]}dx=dS∫∂Ω∂S∂nds+dV∫∂Ω∂V∂nds+dI∫∂Ω∂I∂nds+dR∫∂Ω∂R∂nds+Λ∗|Ω|−μ∗U(t)=Λ∗|Ω|−μ∗U(t). |
By Lemma 2.3, we can obtain that
U(t)≤U(0)e−μ∗t+Λ∗|Ω|μ∗(1−e−μ∗t). |
So U(t)≤max{U(0),Λ∗|Ω|μ∗}, where
U(0)=∫Ω[S(x,0)+V(x,0)+I(x,0)+R(x,0)]dx≤∫Ω‖S(x,0)+V(x,0)+I(x,0)+R(x,0)‖∞dx=‖S(x,0)+V(x,0)+I(x,0)+R(x,0)‖∞|Ω|. |
This shows that U(t)=∫Ω(S+V+I+R)dx is bounded. By Theorem 2.2, we obtain that
‖S+V+I+R‖L1(Ω)=∫Ω|S+V+I+R|(x,t)dx=∫Ω(S+V+I+R)(x,t)dx≤max{‖S(x,0)+V(x,0)+I(x,0)+R(x,0)‖∞|Ω|,Λ∗|Ω|μ∗}. |
We denote that K=max{‖S(x,0)+V(x,0)+I(x,0)+R(x,0)‖∞|Ω|,Λ∗|Ω|μ∗}, then we know
∫Ω(S+V+I+R)dx≤K. |
In view of [62,Lemma 2.1], there exists a positive constant K∗ depending on K such that
‖S+V+I+R‖L∞(Ω)≤K∗. |
Thus, we can obtain that S(x,t),V(x,t),I(x,t),R(x,t) are uniformly bounded on ¯Ω. This implies the boundedness of the solution of system (2.1).
By [60,Corollary 11.3.2] we can deduce that the saturated solution u(t)=(S(x,t),V(x,t),I(x,t),R(x,t)) is either global or limt→+∞‖u(t)‖Y=+∞. From Theorem 2.4 we know that u(t) is bounded, hence, u(t) is a global solution.
In this section, we will analyze the qualitative behavior of system (2.1). It is clearly seen that system (2.1) admits a disease-free equilibrium E0(x)=(S0(x),V0(x),0,0), then we prove that the existence of principal eigenvalues of system (2.1). Linearizing the second and the third equations of (2.1) at disease-free equilibrium, we get
{∂I∂t=dIΔI+[β1(x)+β2(x)]I+ρ(x)R−[μ(x)+η1(x)+ϕ(x)]I, x∈Ω,t>0,∂R∂t=dRΔR+ϕ(x)I−[ρ(x)+μ(x)+η2(x)]R, x∈Ω,t>0,∂I∂n=∂R∂n=0, x∈∂Ω,t>0. | (3.1) |
Let I=eλtφ(x),R=eλtψ(x), equations (3.1) can be rewritten as
{dIΔφ(x)+[β1(x)+β2(x)−(μ(x)+η1(x)+ϕ(x))]φ(x)+ρ(x)ψ(x)=λφ(x), x∈Ω,dRΔψ(x)+ϕ(x)φ(x)−[ρ(x)+μ(x)+η2(x)]ψ(x)=λψ(x), x∈Ω,∂φ∂n=∂ψ∂n=0, x∈∂Ω. | (3.2) |
Denote Φ(x)=(φ(x),ψ(x))T,D=[dI00dR] and
M(x)=(mij(x))=[β1(x)+β2(x)−(μ(x)+η1(x)+ϕ(x))ρ(x)ϕ(x)−[ρ(x)+μ(x)+η2(x)]], |
where mij(x)≥0,i≠j,x∈¯Ω. Therefore, equations (3.2) can be rewritten as
{λΦ(x)=DΔΦ(x)+M(x)Φ(x), x∈Ω,∂Φ∂n=0, x∈∂Ω | (3.3) |
By [59,Theorem 7.6.1], we can obtain that there exists a real eigenvalue λ∗ of Eq (3.3) and a corresponding eigenvector Φ∗(x) satisfying Φ∗(x)>>0 for all x∈¯Ω in the case of Neumann boundary conditions.
Before discussing the global dynamics of the reaction-diffusion SVIR model with relapse and spatial heterogeneous in detail, we need to recall some concept and existing results of exponential attractor and measure of noncompactness.
Let X be a Banach space with the decomposition
X=X1⊕X2; dimX1<∞ |
and denote orthogonal projector by P:X→X1 and (I−P):X→X2. In addition, let {Q(t)}t≥0 be a continuous semigroup on X. The following Condition (C*) introduced in [53] is an important condition for verifying the global exponential attraction.
Condition (C*): For any bounded set B⊂X there exist positive constants tB,C and α such that for any ε>0 there exists a finite dimensional subspace X1⊂X satisfies
{‖PQ(t)B‖}t≥tB is bounded, |
‖(I−P)Q(t)B‖<Ce−αt+ε for t≥tB, |
where P:X→X1 is a orthogonal projector.
In the following, we denote that H=L2(Ω)∩C2,1(Ω), H1=H10(Ω)∩C2,1(Ω),H4=H×H×H×H and H41=H1×H1×H1×H1. Note that H4 and H41 are Banach spaces equipped with norm
‖(S,V,I,R)T‖H4:=max{‖S‖H,‖V‖H,‖I‖H,‖R‖H}. |
and
‖(S,V,I,R)T‖H41:=max{‖S‖H1,‖V‖H1,‖I‖H1,‖R‖H1}. |
Definition 3.1. ([49,Definition A.2.1]) A mapping L+G:H1→H is called a gradient-type operator if there exists a C1 functional F:H1→R1 and for some constant C>0 such that DF(u)⊂H for every u∈Hβ for some β≤1, and
⟨DF(u),Lu+G(u)⟩H≤−C1‖DF(u)‖2H, ∀u∈H1, |
DF(u0)=0⇔Lu0+G(u0)=0. |
In this case, F is called the energy functional of L+G.
Theorem 3.2. System (2.1) exists a global exponential attract set A∗, it exponential attracts any bounded set in H4.
Proof. It is known by the existence of the global solution that if ∀φ=u(0)=(S0(x),V0(x),I0(x),R0(x))T∈H41, then system (2.1) has a global solution u=(S,V,I,R)T∈C0([0,∞),H4). It means that system (2.1) generates a operator semigroup Q(t)=(Q1(t),Q2(t),Q3(t),Q4(t))T and Q(t)φ=u(t,φ).
We first prove that the operator semigroup Q(t) has an absorbing set BˆR⊂H4. It follows from the inner product of the first equation of system (2.1) in H with S, we have that
⟨dSΔS+Λ(x)−β1(x)SIS+I−[μ(x)+α(x)]S,S⟩H=dS∫ΩSΔSdx+∫ΩΛ(x)Sdx−∫Ωβ1(x)S2IS+Idx−∫Ω[μ(x)+α(x)]S2dx≤−dS‖S‖2H12+∫ΩΛ(x)Sdx≤−dS‖S‖2H12+Λ∗∫ΩSdx, |
where H12 is the fractional power subspace generated by the sectorial operator L. From Theorem 2.2 and Theorem 2.4, we can obtain that S is positive and bounded. Hence, there exists a C1>0 such that
Λ∗∫ΩSdx≤C1. |
Since H12↪H, so there exists a C>0, such that
‖S‖H12≥C‖S‖H, ∀S∈H12. |
As we know that
12ddt⟨S,S⟩H=⟨St,S⟩H, |
hence,
12ddt‖S‖2H≤−dSC2‖S‖2H+C1, |
By Lemma 2.3, we obtain that
‖S‖2H≤e−γ1t‖S0(x)‖2H+2C1γ1(1−e−γ1t), |
where γ1=2dSC2. It follows from the inner product of the second equation of system (2.1) in H with V, we have that
⟨dVΔV+α(x)S−β2(x)VIV+I−μ(x)V,V⟩H=dV∫ΩVΔVdx+∫Ωα(x)SVdx−∫Ωβ2(x)V2IV+Idx−∫Ωμ(x)V2dx≤−dV‖V‖2H12+α∗∫ΩSVdx, |
From Theorem 2.2 and Theorem 2.4, we can obtain that S,V are positive and bounded. Hence, there exists a C2>0 such that
α∗∫ΩSVdx≤C2. |
Since H12↪H, so there exists a C>0, such that
‖V‖H12≥C‖V‖H, ∀V∈H12. |
Hence,
12ddt‖V‖2H≤−dVC2‖V‖2H+C2, |
By Lemma 2.3, we obtain that
‖V‖2H≤e−γ2t‖V0(x)‖2H+2C2γ2(1−e−γ2t), |
where γ2=2dVC2. It follows from the inner product of the third equation of system (2.1) in H with I, we have that
⟨dIΔI+β1(x)SIS+I+β2(x)VIV+I+ρ(x)R−[μ(x)+η1(x)+ϕ(x)]I,I⟩H=dI∫ΩIΔIdx+∫Ωβ1(x)SI2S+Idx+∫Ωβ2(x)VI2V+Idx+∫Ωρ(x)IRdx−∫Ω[μ(x)+η1(x)+ϕ(x)]I2dx≤−dI‖I‖2H12+∫Ωβ1(x)SI2S+Idx+∫Ωβ2(x)VI2V+Idx+∫Ωρ(x)IRdx≤−dI‖I‖2H12+(β∗1+β∗2)∫ΩI2dx+ρ∗∫ΩIRdx, |
From Theorem 2.2 and Theorem 2.4, we can obtain that I,R are positive and bounded. Hence, there exists a C3>0 such that
(β∗1+β∗2)∫ΩI2dx+ρ∗∫ΩIRdx≤C35. |
Since H12↪H, so there exists a C>0, such that
‖I‖H12≥C‖I‖H, ∀I∈H12. |
Hence,
12ddt‖I‖2H≤−dIC2‖I‖2H+C3, |
By Lemma 2.3, we obtain that
‖I‖2H≤e−γ3t‖I0(x)‖2H+2C3γ3(1−e−γ3t), |
where γ3=2dIC2. It follows from the inner product of the forth equation of system (2.1) in H with R, we have that
⟨dRΔR+ϕ(x)I−[ρ(x)+μ(x)+η2(x)]R,R⟩H=dR∫ΩRΔRdx+∫Ωϕ(x)IRdx−∫Ω[ρ(x)+μ(x)+η2(x)]R2dx≤−dR‖R‖2H12+ϕ∗∫ΩIRdx. |
From Theorem 2.2 and Theorem 2.4, we can obtain that there exists a C4>0 such that
ϕ∗∫ΩIRdx≤C4. |
Since H12↪H, so there exists a C>0, such that
‖R‖H12≥C‖R‖H, ∀R∈H12. |
Hence,
12ddt‖R‖2H≤−dRC2‖R‖2H+C4, |
By Lemma 2.3, we obtain that
‖R‖2H≤e−γ4t‖R0(x)‖2H+2C4γ4(1−e−γ4t), |
where γ4=2dRC2. Therefore, it implies if ˆR2>max{2C1γ1,2C2γ2,2C3γ3,2C4γ4}, then there exists a t0>0, such that for any t≥t0, there has u(t,φ)⊂BˆR. Thence, BˆR⊂H4 is the absorbing set.
Next we verify Condition (C*). Since L1=dSΔ:H1→H is a symmetrical sectorial operator, so the eigenvectors {ej}j∈N corresponding to the eigenvalues {λS,j}j∈N are the complete orthonormal basis of H, that is for any S∈H,
S=∞∑k=1xkek,‖S‖2H=∞∑k=1x2k. |
In addition, ∀NS>0,∃KS≥1 such that −NS≥λS,j,∀j≥KS+1.
Let
HKS1=span{e1,e2,...,eKS} and HKS2=(HKS1)⊥. |
Then, each S∈H can be decomposed as
S=PS+(I−P)S:=S1+S2,S1=KS∑i=1xiei∈HKS1, S2=∞∑j=KS+1xjej∈HKS2, |
where P:H→HKS1 is the orthogonal projector. There are similar decomposition forms for each V,I,R∈H.
Since Q(t) has a bounded absorbing set BˆR⊂H4, then for any bounded set B⊂H4, there exists a tB>0, without loss of generality, we assume that tB>t0 such that (S(t,S0(x)),V(t,V0(x)),I(t,I0(x)),R(t,R0(x)))⊂BˆR, where
S(t,S0(x))=Q1(t)S0(x),V(t,V0(x))=Q2(t)V0(x),I(t,I0(x))=Q3(t)I0(x),R(t,R0(x))=Q4(t)R0(x), |
∀(S0(x),V0(x),I0(x),R0(x))∈B,t≥tB, then
‖S(t,S0(x))‖2H=‖Q1(t)S0(x)‖2H≤ˆR2,∀t≥tB,‖V(t,V0(x))‖2H=‖Q2(t)V0(x)‖2H≤ˆR2,∀t≥tB,‖I(t,I0(x))‖2H=‖Q3(t)I0(x)‖2H≤ˆR2,∀t≥tB,‖R(t,R0(x))‖2H=‖QR(t)R0(x)‖2H≤ˆR2,∀t≥tB. |
Hence,
‖PQ(t)φ‖H4≤ˆR, ∀t≥tB. |
It means that {‖PQ(t)B‖H4}t≥tB is bounded.
It follows from the inner product of the first equation of system (2.1) in H with S2, we have that
12ddt⟨S,S2⟩H=⟨St,S2⟩H=⟨dSΔS+Λ(x)−β1(x)SIS+I−[μ(x)+α(x)]S,S2⟩H=⟨dSΔS,S2⟩H+⟨Λ(x)−β1(x)SIS+I−[μ(x)+α(x)]S,S2⟩H=⟨dSΔS1+dSΔS2,S2⟩H+⟨Λ(x)−β1(x)SIS+I−[μ(x)+α(x)]S,S2⟩H≤⟨dSΔS2,S2⟩H+⟨Λ(x)−β1(x)SIS+I−[μ(x)+α(x)]S,S2⟩H, |
where
⟨dSΔS2,S2⟩H=−dS‖S2‖2H12=dS∞∑j=KS+1λS,jx2j≤−dSNS∞∑j=KS+1x2j=−dSNS‖S2‖2H. |
Since t≥tB, ‖S‖H≤ˆR. Then
⟨Λ(x)−β1(x)SIS+I−[μ(x)+α(x)]S,S2⟩H≤‖Λ(x)−β1(x)SIS+I−[μ(x)+α(x)]S‖H‖S2‖H≤(‖Λ(x)‖H+‖β1(x)S‖H+‖[μ(x)+α(x)]S‖H)ˆR≤[Λ∗+(β∗1+μ∗+α∗)ˆR]ˆR:=CS,ˆR. |
Hence,
ddt‖S2‖2H≤−2dSNS‖u2‖2H+2CS,ˆR. |
By Lemma 2.3,
‖S2‖2H≤e−2dSNS(t−tB)‖S2(tB)‖2H+CS,ˆRdSNS(1−e−2dSNS(t−tB)), ∀t≥tB |
and NS>0 is arbitrary. Similarly,
‖V2‖2H≤e−2dVNV(t−tB)‖V2(tB)‖2H+CV,ˆRdVNV(1−e−2dVNV(t−tB)), ∀t≥tB, |
‖I2‖2H≤e−2dINI(t−tB)‖I2(tB)‖2H+CI,ˆRdINI(1−e−2dINI(t−tB)), ∀t≥tB, |
‖R2‖2H≤e−2dRNR(t−tB)‖R2(tB)‖2H+CR,ˆRdRNR(1−e−2dRNR(t−tB)), ∀t≥tB |
and NV,NI,NR>0 are arbitrary. Therefore, we deduce that the Condition (C*) holds. By [53,Theorem 4.1], we obtain that system (2.1) has a global exponential attract set A∗.
After getting the global exponential attract set, we discuss the stability and uniform persistence of the epidemic disease.
Theorem 3.3. The following statements are valid.
(1) If λ∗<0, then
limt→∞S(x,t)=S0(x),limt→∞V(x,t)=V0(x),limt→∞I(x,t)=0,limt→∞R(x,t)=0 |
in H, and hence, the disease-free equilibrium is globally asymptotically stable.
(2) If λ∗>0, then there exists a function γ(x)>0 independent of the initial data, such that any solution (S,V,I,R) satisfies
liminft→∞S(x,t)≥γ(x),liminft→∞V(x,t)≥γ(x),liminft→∞I(x,t)≥γ(x),liminft→∞R(x,t)≥γ(x) |
for x∈¯Ω, and hence, the disease persists uniformly.
Proof. (1) Suppose λ∗<0. Using the comparison principle, we can show that I(x,t)→0,R(x,t)→0 as t→∞ for every x∈Ω. First, we observe from the system (2.1) that
{∂I∂t≤dIΔI+{β1(x)+β2(x)−[μ(x)+η1(x)+ϕ(x)]}I+ρ(x)R, x∈Ω,t>0,∂R∂t≤dRΔR+ϕ(x)I−[ρ(x)+μ(x)+η2(x)]R, x∈Ω,t>0. |
Next, let us define (˜I(x,t),˜R(x,t))=(Meλ∗tφ∗(x),Meλ∗tψ∗(x)) where λ∗<0,φ∗(x)>>0,ψ∗(x)>>0 are the eigenvalue and eigenvectors in equations (3.2) and M is chosen so large that I(x,0)≤˜I(x,0),R(x,0)≤˜R(x,0) for every x∈Ω. It can be easily shown that (˜I(x,t),˜R(x,t)) satisfies
{∂˜I∂t=dIΔ˜I+{β1(x)+β2(x)−[μ(x)+η1(x)+ϕ(x)]}˜I+ρ(x)˜R, x∈Ω,t>0,∂˜R∂t=dRΔ˜R+ϕ(x)˜I−[ρ(x)+μ(x)+η2(x)]˜R, x∈Ω,t>0,∂˜I∂n=∂˜R∂n=0, x∈∂Ω. |
By the comparison principle Lemma 2.1, I(x,t)≤˜I(x,t),R(x,t)≤˜R(x,t) for every x∈Ω and t≥0. Since ˜I(x,t)→0,˜R(x,t)→0 as t→∞ for every x∈Ω, we also have that I(x,t)→0,R(x,t)→0 as t→∞ for every x∈Ω.
Next we claim S(⋅,t)→S0(x) uniformly on as t→∞. Given any small constant ε>0, there exists a large time T>0 such that 0≤I(x,t)≤ε for all x∈¯Ω,t≥T. From the first equation in system (2.1), it is easily observed that S is a super-solution to
{∂w∂t−dSΔw=Λ(x)−β∗1ε−[μ(x)+α(x)]w, x∈Ω,t≥T,∂w∂n=0, x∈∂Ω,w(x,T)=S(x,T), x∈Ω | (3.4) |
and a sub-solution to
{∂v∂t−dSΔv=Λ(x)−[μ(x)+α(x)]v, x∈Ω,t≥T,∂v∂n=0, x∈∂Ω,v(x,T)=S(x,T), x∈Ω. | (3.5) |
Denote by w and v the solution of system (3.4) and system (3.5), respectively. The parabolic comparison principle gives
w(x,t)≤S(x,t)≤v(x,t) for all x∈¯Ω,t≥T. |
For system (3.4), we can verify that
⟨dSΔw+Λ(x)−β∗1ε−[μ(x)+α(x)]w,w⟩H=dS∫ΩwΔwdx+∫ΩΛ(x)wdx−∫Ωβ∗1εwdx−∫Ω[μ(x)+α(x)]w2dx≤−dS‖w‖2H12+Λ∗∫Ωwdx. |
It is similar to the proof of Theorem 3.2, we can obtain that system (3.4) exists a global exponential attract set Aw. In addition, system (3.4) has a variational structure, the corresponding functional of the variational structure is
F(w)=∫Ω[dS2|∇w|2−g(x,w)]dx, |
where
g(x,w)=∫w0[Λ(x)−β∗1ε−[μ(x)+α(x)]w]dw. |
Then
⟨DF(w),Lw+G(w)⟩H=⟨DF(w),dSΔw+Λ(x)−β∗1ε−[μ(x)+α(x)]w⟩H≤−C‖DF(w)‖2H, |
where C>0, so L+G is a gradient type operator. From [49,Theorem A.2.2], we can prove that
limt→∞w(x,t)=S0−(ε,x) in H, |
where S0−(ε,x) is the unique positive steady state of problems (3.4). Similarly, for system (3.5), we can obtain
limt→∞v(x,t)=S0(x) in H, |
where S0(x) is the unique positive steady state of problems (3.5). Furthermore, due to the arbitrariness of ε, it is checked that
S0−(ε,x)→S0(x) in H, as ε→0. |
Thus, our analysis implies that S(⋅,t)→S0(x) uniformly on as t→∞. Similarly, we can also prove that V(⋅,t)→V0(x) uniformly on as t→∞.
(2) Since λ∗>0. It is observed that the solution of
{∂S−∂t−dSΔS−=Λ(x)−[β1(x)+μ(x)+α(x)]S−, x∈Ω,t≥T,∂S−∂n=0, x∈∂Ω,S−(x,T)=S(x,T), x∈Ω | (3.6) |
is a sub-solution of the first equation in (2.1). Similar to the proof of conclusion (1), system (3.6) is also a gradient type equation. From [49,Theorem A.2.2], we can prove that
limt→∞S−(x,t)=S∗−(x) in H, |
By weak maximum principle, we know that S∗−(x)>0 for all x∈Ω. Similarly, we can also prove that V∗−(x)>0 for all x∈Ω. Next, let us define (I−(x,t),R−(x,t))=(εφ∗(x),εψ∗(x)) where φ∗(x)>>0,ψ∗(x)>>0 are the eigenvalue and eigenvectors in equations (3.2) and ε>0 is a sufficiently small constant. Substituting εφ∗,εψ∗ into the third and the forth equations of system (2.1), we know
εdIΔφ∗+β1(x)Sεφ∗S+εφ∗+β2(x)V∗εφ∗V∗+εφ∗+ερ(x)ψ∗−ε[μ(x)+η1(x)+ϕ(x)]φ∗−∂(εφ∗)∂t=εdIΔφ∗+β1(x)Sεφ∗S+εφ∗+β2(x)V∗εφ∗V∗+εφ∗+ερ(x)ψ∗−ε[μ(x)+η1(x)+ϕ(x)]φ∗+εβ1(x)φ∗−εβ1(x)φ∗+εβ2(x)φ∗−εβ2(x)φ∗=ε{dIΔφ∗+[β1(x)+β2(x)]φ∗−[μ(x)+η1(x)+ϕ(x)]φ∗+ρ(x)ψ∗}+εβ1(x)φ∗[S∗S∗+εφ∗−1]+εβ2(x)φ∗[V∗V∗+εφ∗−1]=εφ∗[λ∗+β1(x)(S∗S∗+εφ∗−1)+β2(x)(V∗V∗+εφ∗−1)]>0 |
and
εdRΔψ∗+εϕ(x)φ∗−ε[ρ(x)+μ(x)+η2(x)]ψ∗−∂(εψ∗)∂t=ε[dRΔψ∗+ϕ(x)φ∗−[ρ(x)+μ(x)+η2(x)]ψ∗]=ελ∗ψ∗>0. |
Therefore, (εφ∗,εψ∗) is the sub-solution of the third and the forth equations of system (2.1). We choose 0<γ(x)<min{S∗−(x),V∗−(x),εφ∗(x),εψ∗(x)}, we can obtain that
liminft→∞S(x,t)≥γ(x),liminft→∞V(x,t)≥γ(x),liminft→∞I(x,t)≥γ(x),liminft→∞R(x,t)≥γ(x) |
for x∈¯Ω, then it shows that the disease persists.
The synthesis of Theorem 3.2 and Theorem 3.3 can give the following results: if λ∗>0, then the positive solution of system (2.1) is globally exponential attractive and the attraction domain is A∗. From an epidemiological point of view, the disease persists in this situation. The epidemic is globally asymptotically stable or attracted by the global exponential attract set.
In this section, we hope to select a specific epidemic disease with some more practical and more definitive data to simulate the stability of our SVIR model with relapse. As we know, HBV epidemic model is a kind of infectious disease model with relapse and vaccination is the most effective way to prevent hepatitis. WHO also releases global hepatitis report every year. From "Global Hepatitis Report, 2017" [63], we know that in worldwide, approximately 240 million people have chronic hepatitis B virus infection. Without an expanded and accelerated response, the number of people living with hepatitis B virus is projected to remain at the current, high levels for the next 40-50 years, with a cumulative 20 million deaths occurring between 2015 and 2030. A stepped-up global response can no longer be delayed. From World Health Statistics [64], we can find that the data of global natural mortality, the male natural mortality rate is 19% and female natural mortality rate is 12.9% respectively. After a simple calculation we can get the natural mortality rate of the global is 15.95%. In conclusion, we can get the data in Table 2.
Parameter | Description | Data estimated | Data sources |
Λ | Recruitment scale of the population. | 300year−1 | [63] |
β1 | Estimated HBV prevalence (Transmission rate) without vaccination. | 0.062year−1 | [63] |
β2 | Estimated HBV prevalence (Transmission rate) with vaccination. | 0.035year−1 | [63] |
α | vaccinate rate. | 0.39year−1 | [63] |
ρ | Relapse rate. | 0.3year−1 | Estimate |
ϕ | The per-capita recovery (treatment) rate. | 0.08year−1 | Estimate |
μ | Natural mortality rate. | 0.1595year−1 | [64] |
η1 | The disease-related death rate of the HBV. | 0.2year−1 | [63] |
η2 | The disease-related death rate of being treated. | 0.1year−1 | Estimate |
dS | The diffusion coefficient of susceptible individuals. | 2year−1 | Estimate |
dV | The diffusion coefficient of vaccinated individuals. | 2.5year−1 | Estimate |
dI | The diffusion coefficient of infected individuals. | 1.5year−1 | Estimate |
dR | The diffusion coefficient of restored individuals. | 5year−1 | Estimate |
According to the data in Table 2, we will first simulate the stability of the constant coefficient model about system (2.1) when Λ,β1,β2,α,ρ,ϕ,μ,η1 and η2 are assumed to be positive constants. Then we can obtain the stability of disease-free equilibrium of constant coefficient model (Figure 2).
From the numerical simulation, it can be seen that although hepatitis B is still the primary disease endangering human health, however, the global hepatitis B disease has shown a trend of extinction.
In this article, we discuss the dynamics of the epidemic model with a spatial heterogeneous environment, so we then simulate the stability and persistence of the spatial system (2.1). From the system (2.1) we can see that all the parameters are x−related functions, so we choose different functions will directly lead to different stability results. We choose β1(x)=11+x,μ(x)=e−2x,ϕ(x)=e−x,ρ(x)=0.4sinx,η1(x)=0.2,η2(x)=0.1 and select other parameters from Table 2. We can show the global stability of non-constant disease-free equilibrium E0(x) of system (2.1) (Figure 3).
We choose μ(x)=e−x,ϕ(x)=11+x,β1(x)=0.62,β2(x)=0.33e−x and select other parameters from Table 2. We can obtain that the spatial heterogeneity epidemic is global stability (Figure 4).
We choose μ(x)=e−x,ϕ(x)=11+x,ρ(x)=0.4sinx,β1(x)=0.62,β2(x)=0.33e−x and select other parameters from Table 2. We can clearly see that the spatial heterogeneity epidemic is persists uniformly (Figure 5).
In Figure 5, we can find that the image of the solution is turbulent, and the amplitude decreases with time. Finally, the image of the turmoil is controlled in range. And this range is the scope of the global exponential attract set. From the comparison of Figure 4 and Figure 5, we can find that spatial heterogeneity has a great impact on the spread of disease, and different parameters lead to changes in long-term dynamic behavior.
From all above simulation we can clearly see that the disease-free equilibrium of the constant-coefficient model is global asymptotic stability. For spatial heterogeneous models, the stability of the model is dependent on the spatial parameters and diffusion coefficients. In addition, we can also see that the image whether rising or falling is very fast in the initial stage, which also confirms that the solutions of system (2.1) are global exponential attract.
We have formulated a reaction-diffusion SVIR model with relapse in the spatially heterogeneous environment. We first prove the positivity of solution by using the comparison principle of monotone nonlinear reaction-diffusion dynamical system and comparison principle of parabolic equation. Most of the models in the previous work are non-coupled models or systems that contain only one diffusion equation. The usual way to study these two problems is to study one of the equations in the model first (such as eigenvalue problems or the existence of solutions), and then to get the properties of several other equations. However, the above methods do not applicable to the coupling system of the four diffusion equations we have established in this paper. In addition, we prove that the disease-free equilibrium is globally asymptotically stable and the endemic is persisting uniformly by the global exponential attract set theory. From our proof, we can find that λ∗ has threshold characteristics. From the numerical simulation we can find the effect of spatial heterogeneity on the diffusion of disease is very large. Simulation results show that the best way to eliminate the disease is to control the contact rate. Reduce the relapse rate or increase the vaccination rate can make the disease tends to a stable state. Choosing different spatial coefficients can produce a fundamental change of the global dynamics of the system.
The authors would like to thank the anonymous referees for their useful and valuable suggestions. The first author was supported by the Fundamental Research Funds for the Central Universities (JUSRP11949), NSF of China (11671180, 11671181) and the third author was supported by the science and technology foundation of Suqian(Z201444), China.
The authors declare there is no conflict of interest.
[1] | Mukkamalla SKR, Recio-Boiles A, Babiker HM (2024) Gastric Cancer. Florida: StatPearls Publishing. Available from: http://www.ncbi.nlm.nih.gov/books/NBK459142/ |
[2] |
De Martel C, Forman D, Plummer M (2013) Gastric cancer. Gastroenterol Clin North Am 42: 219-240. https://doi.org/10.1016/j.gtc.2013.01.003 ![]() |
[3] |
Karimi P, Islami F, Anandasabapathy S, et al. (2014) Gastric cancer: Descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev 23: 700-713. https://doi.org/10.1158/1055-9965.EPI-13-1057 ![]() |
[4] |
Rawla P, Barsouk A (2019) Epidemiology of gastric cancer: Global trends, risk factors and prevention. Gastroenterol Rev 14: 26-38. https://doi.org/10.5114/pg.2018.80001 ![]() |
[5] |
Sitarz R, Skierucha M, Mielko J, et al. (2018) Gastric cancer: Epidemiology, prevention, classification, and treatment. Cancer Manage Res 10: 239-248. https://doi.org/10.2147/CMAR.S149619 ![]() |
[6] |
Morgan E, Arnold M, Camargo MC, et al. (2022) The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: A population-based modelling study. EClinicalMedicine 47: 101404. https://doi.org/10.1016/j.eclinm.2022.101404 ![]() |
[7] |
Wong MCS, Huang J, Chan PSF, et al. (2021) Global Incidence and mortality of gastric cancer, 1980–2018. JAMA Network Open 4: e2118457. https://doi.org/10.1001/jamanetworkopen.2021.18457 ![]() |
[8] | Hua MJ Staging efficacy: Cancer treatment in contemporary China (2020). https://doi.org/10.6082/uchicago.2753 |
[9] |
Lin JL, Lin JX, Lin GT, et al. (2024) Global incidence and mortality trends of gastric cancer and predicted mortality of gastric cancer by 2035. BMC Public Health 24: 1763. https://doi.org/10.1186/s12889-024-19104-6 ![]() |
[10] |
Miller KD, Nogueira L, Mariotto AB, et al. (2019) Cancer treatment and survivorship statistics, 2019. CA A Cancer J Clinicians 69: 363-385. https://doi.org/10.3322/caac.21565 ![]() |
[11] |
Miller KD, Nogueira L, Devasia T, et al. (2022) Cancer treatment and survivorship statistics, 2022. Ca-Cancer J Clin 72: 409-436. https://doi.org/10.3322/caac.21731 ![]() |
[12] |
Malik A, Ali F, Malik MI, et al. (2024) The risk of infection-caused mortality in gastric adenocarcinoma: A population-based study. Gastroenterol Res 17: 133-145. https://doi.org/10.14740/gr.v17i3.1715 ![]() |
[13] |
Assumpção PP, Barra WF, Ishak G, et al. (2020) The diffuse-type gastric cancer epidemiology enigma. BMC Gastroenterol 20: 223. https://doi.org/10.1186/s12876-020-01354-4 ![]() |
[14] |
Iyer P, Moslim M, Farma JM, et al. (2020) Diffuse gastric cancer: Histologic, molecular, and genetic basis of disease. Transl Gastroenterol Hepatol 5: 52. https://doi.org/10.21037/tgh.2020.01.02 ![]() |
[15] |
Mabula JB, Mchembe MD, Koy M, et al. (2012) Gastric cancer at a university teaching hospital in northwestern Tanzania: A retrospective review of 232 cases. World J Surg Oncol 10: 257. https://doi.org/10.1186/1477-7819-10-257 ![]() |
[16] |
Iwu CD, Iwu-Jaja CJ (2023) Gastric cancer epidemiology: Current trend and future direction. Hygiene 3: 256-268. https://doi.org/10.3390/hygiene3030019 ![]() |
[17] |
Rugge M, Fassan M, Graham DY (2015) Epidemiology of gastric cancer. Gastric Cancer. Cham: Springer International Publishing 23-34. https://doi.org/10.1007/978-3-319-15826-6_2 ![]() |
[18] |
Ferro A, Peleteiro B, Malvezzi M, et al. (2014) Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype. Eur J Cancer 50: 1330-1344. https://doi.org/10.1016/j.ejca.2014.01.029 ![]() |
[19] |
Machlowska J, Baj J, Sitarz M, et al. (2020) Gastric cancer: Epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci 21: 4012. https://doi.org/10.3390/ijms21114012 ![]() |
[20] |
Hu Y, Huang C, Sun Y, et al. (2016) Morbidity and mortality of laparoscopic versus open D2 distal gastrectomy for advanced gastric cancer: A randomized controlled trial. J Clin Oncol 34: 1350-1357. https://doi.org/10.1200/JCO.2015.63.7215 ![]() |
[21] |
Naran K, Nundalall T, Chetty S, et al. (2018) Principles of immunotherapy: Implications for treatment strategies in cancer and infectious diseases. Front Microbiol 9: 3158. https://doi.org/10.3389/fmicb.2018.03158 ![]() |
[22] |
Hu H, Chen Y, Tan S, et al. (2022) The research progress of antiangiogenic therapy, immune therapy and tumor microenvironment. Front Immunol 13: 802846. https://doi.org/10.3389/fimmu.2022.802846 ![]() |
[23] |
Bilotta MT, Antignani A, Fitzgerald DJ (2022) Managing the TME to improve the efficacy of cancer therapy. Front Immunol 13: 954992. https://doi.org/10.3389/fimmu.2022.954992 ![]() |
[24] |
Samstein RM, Lee CH, Shoushtari AN, et al. (2019) Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 51: 202-206. https://doi.org/10.1038/s41588-018-0312-8 ![]() |
[25] |
Ru B, Wong CN, Tong Y, et al. (2019) TISIDB: An integrated repository portal for tumor–immune system interactions. Bioinformatics 35: 4200-4202. https://doi.org/10.1093/bioinformatics/btz210 ![]() |
[26] |
Bagchi S, Yuan R, Engleman EG (2021) Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance. Annu Rev Pathol Mech Dis 16: 223-249. https://doi.org/10.1146/annurev-pathol-042020-042741 ![]() |
[27] |
Labani-Motlagh A, Ashja-Mahdavi M, Loskog A (2020) The tumor microenvironment: A milieu hindering and obstructing antitumor immune responses. Front Immunol 11: 940. https://doi.org/10.3389/fimmu.2020.00940 ![]() |
[28] |
Zhu Y, Knolhoff BL, Meyer MA, et al. (2014) CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 74: 5057-5069. https://doi.org/10.1158/0008-5472.CAN-13-3723 ![]() |
[29] |
Henke E, Nandigama R, Ergün S (2020) Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front Mol Biosci 6: 160. https://doi.org/10.3389/fmolb.2019.00160 ![]() |
[30] |
Mager LF, Burkhard R, Pett N, et al. (2020) Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 369: 1481-1489. https://doi.org/10.1126/science.abc3421 ![]() |
[31] |
Kon E, Benhar I (2019) Immune checkpoint inhibitor combinations: Current efforts and important aspects for success. Drug Resist Updates 45: 13-29. https://doi.org/10.1016/j.drup.2019.07.004 ![]() |
[32] |
Sobhani N, Tardiel-Cyril DR, Davtyan A, et al. (2021) CTLA-4 in regulatory T cells for cancer immunotherapy. Cancers 13: 1440. https://doi.org/10.3390/cancers13061440 ![]() |
[33] |
Tang Q, Chen Y, Li X, et al. (2022) The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol 13: 964442. https://doi.org/10.3389/fimmu.2022.964442 ![]() |
[34] | Colligan SH Mitigating myeloid-driven pathways of immune suppression to enhance cancer immunotherapy efficacy (2022). |
[35] |
Guzik K, Tomala M, Muszak D, et al. (2019) Development of the inhibitors that target the PD-1/PD-L1 interaction—a brief look at progress on small molecules, peptides and macrocycles. Molecules 24: 2071. https://doi.org/10.3390/molecules24112071 ![]() |
[36] |
Graziani G, Lisi L, Tentori L, et al. (2022) Monoclonal antibodies to CTLA-4 with focus on ipilimumab. Interaction of Immune and Cancer Cells. Cham: Springer International Publishing 295-350. https://doi.org/10.1007/978-3-030-91311-3_10 ![]() |
[37] |
Lipson EJ, Drake CG (2011) Ipilimumab: An anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 17: 6958-6962. https://doi.org/10.1158/1078-0432.CCR-11-1595 ![]() |
[38] |
Rajan A, Kim C, Heery CR, et al. (2016) Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccines Immunother 12: 2219-2231. https://doi.org/10.1080/21645515.2016.1175694 ![]() |
[39] |
Massard C, Gordon MS, Sharma S, et al. (2016) Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death Ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 34: 3119-3125. https://doi.org/10.1200/JCO.2016.67.9761 ![]() |
[40] |
Peters S, Kerr KM, Stahel R (2018) PD-1 blockade in advanced NSCLC: A focus on pembrolizumab. Cancer Treat Rev 62: 39-49. https://doi.org/10.1016/j.ctrv.2017.10.002 ![]() |
[41] |
Inman BA, Longo TA, Ramalingam S, et al. (2017) Atezolizumab: A PD-L1–blocking antibody for bladder cancer. Clin Cancer Res 23: 1886-1890. https://doi.org/10.1158/1078-0432.CCR-16-1417 ![]() |
[42] |
Teets A, Pham L, Tran EL, et al. (2018) Avelumab: A novel anti-PD-L1 agent in the treatment of merkel cell carcinoma and urothelial cell carcinoma. Crit Rev Immunol 38: 159-206. https://doi.org/10.1615/CritRevImmunol.2018025204 ![]() |
[43] | Rath B, Plangger A, Hamilton G (2020) Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer. Cancer Drug Res 3: 171. https://doi.org/10.20517/cdr.2019.85 |
[44] |
Villani A, Ocampo-Garza SS, Potestio L, et al. (2022) Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma. Expert Opin Drug Saf 21: 21-29. https://doi.org/10.1080/14740338.2022.1993819 ![]() |
[45] |
Mirza MR, Chase DM, Slomovitz BM, et al. (2023) Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Me 388: 2145-2158. https://doi.org/10.1056/NEJMoa2216334 ![]() |
[46] |
Patel TH, Brewer JR, Fan J, et al. (2024) FDA approval summary: Tremelimumab in combination with durvalumab for the treatment of patients with unresectable hepatocellular carcinoma. Clin Cancer Res 30: 269-273. https://doi.org/10.1158/1078-0432.CCR-23-2124 ![]() |
[47] | Burtness B Toripalimab yields ‘Striking’ PFS improvement in nasopharyngeal carcinoma (2024). Available from: https://www.cancernetwork.com/view/toripalimab-yields-striking-pfs-improvement-in-nasopharyngeal-carcinoma |
[48] |
Rugo HS, Kabos P, Beck JT, et al. (2022) Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study. npj Breast Cancer 8: 1-8. https://doi.org/10.1038/s41523-022-00482-2 ![]() |
[49] |
Deng Y, Huang M, Deng R, et al. (2024) Immune checkpoint inhibitor-related adrenal hypofunction and Psoriasisby induced by tislelizumab: A case report and review of literature. Medicine 103: e37562. https://doi.org/10.1097/MD.0000000000037562 ![]() |
[50] |
Reuss JE, Gosa L, Liu SV (2021) Antibody drug conjugates in lung cancer: State of the current therapeutic landscape and future developments. Clin Lung Cancer 22: 483-499. https://doi.org/10.1016/j.cllc.2021.07.011 ![]() |
[51] |
Brahmer JR, Tykodi SS, Chow LQM, et al. (2012) Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465. https://doi.org/10.1056/NEJMoa1200694 ![]() |
[52] |
Dermani FK, Samadi P, Rahmani G, et al. (2019) PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy. J Cell Physiol 234: 1313-1325. https://doi.org/10.1002/jcp.27172 ![]() |
[53] |
Lai X, Friedman A (2017) Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: A mathematical model. BMC Syst Biol 11: 70. https://doi.org/10.1186/s12918-017-0446-9 ![]() |
[54] |
Zhang Q, Shao B, Tong Z, et al. (2022) A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer. BMC Med 20: 321. https://doi.org/10.1186/s12916-022-02527-6 ![]() |
[55] |
Dazio G, Epistolio S, Frattini M, et al. (2022) Recent and future strategies to overcome resistance to targeted therapies and immunotherapies in metastatic colorectal cancer. J Clin Med 11: 7523. https://doi.org/10.3390/jcm11247523 ![]() |
[56] |
Liu Y, Zhang X, Wang G, et al. (2021) Triple combination therapy with PD-1/PD-L1, BRAF, and MEK inhibitor for stage III–IV melanoma: A systematic review and meta-analysis. Front Oncol 11: 693655. https://doi.org/10.3389/fonc.2021.693655 ![]() |
[57] |
Stein MK, Oluoha O, Patel K, et al. (2021) Precision medicine in oncology: A review of multi-tumor actionable molecular targets with an emphasis on non-small cell lung cancer. J Pers Med 11: 518. https://doi.org/10.3390/jpm11060518 ![]() |
[58] |
Musacchio L, Cicala CM, Camarda F, et al. (2022) Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: A new perspective on the horizon?. ESMO Open 7: 100536. https://doi.org/10.1016/j.esmoop.2022.100536 ![]() |
[59] |
Rizvi H, Sanchez-Vega F, La K, et al. (2018) Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-Ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol 36: 633-641. https://doi.org/10.1200/JCO.2017.75.3384 ![]() |
[60] |
Gettinger S, Choi J, Hastings K, et al. (2017) Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Disco 7: 1420-1435. https://doi.org/10.1158/2159-8290.CD-17-0593 ![]() |
[61] |
Sibaud V (2018) Dermatologic Reactions to immune checkpoint inhibitors: Skin toxicities and immunotherapy. Am J Clin Dermatol 19: 345-361. https://doi.org/10.1007/s40257-017-0336-3 ![]() |
[62] |
Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359: 1350-1355. https://doi.org/10.1126/science.aar4060 ![]() |
[63] |
Vétizou M, Pitt JM, Daillère R, et al. (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350: 1079-1084. https://doi.org/10.1126/science.aad1329 ![]() |
[64] |
Van Allen EM, Miao D, Schilling B, et al. (2015) Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350: 207-211. https://doi.org/10.1126/science.aad0095 ![]() |
[65] |
Wang DY, Salem JE, Cohen JV, et al. (2018) Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncol 4: 1721. https://doi.org/10.1001/jamaoncol.2018.3923 ![]() |
[66] |
Rowshanravan B, Halliday N, Sansom DM (2018) CTLA-4: A moving target in immunotherapy. Blood 131: 58-67. https://doi.org/10.1182/blood-2017-06-741033 ![]() |
[67] |
Qin S, Xu L, Yi M, et al. (2019) Novel immune checkpoint targets: Moving beyond PD-1 and CTLA-4. Mol Cancer 18: 155. https://doi.org/10.1186/s12943-019-1091-2 ![]() |
[68] |
Rizvi NA, Hellmann MD, Snyder A, et al. (2015) Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science 348: 124-128. https://doi.org/10.1126/science.aaa1348 ![]() |
[69] |
Routy B, Le Chatelier E, Derosa L, et al. (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359: 91-97. https://doi.org/10.1126/science.aan3706 ![]() |
[70] |
Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition. Amn J Clin Oncolo 39: 98-106. https://doi.org/10.1097/COC.0000000000000239 ![]() |
[71] |
Alsaab HO, Sau S, Alzhrani R, et al. (2017) PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome. Front Pharmacol 8: 561. https://doi.org/10.3389/fphar.2017.00561 ![]() |
[72] |
Champiat S, Dercle L, Ammari S, et al. (2017) Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 23: 1920-1928. https://doi.org/10.1158/1078-0432.CCR-16-1741 ![]() |
[73] |
Wang Y, Zhou S, Yang F, et al. (2019) Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis. JAMA Oncol 5: 1008. https://doi.org/10.1001/jamaoncol.2019.0393 ![]() |
[74] |
Yi M, Zheng X, Niu M, et al. (2022) Combination strategies with PD-1/PD-L1 blockade: Current advances and future directions. Mol Cancer 21: 28. https://doi.org/10.1186/s12943-021-01489-2 ![]() |
[75] |
Akinleye A, Rasool Z (2019) Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol 12: 92. https://doi.org/10.1186/s13045-019-0779-5 ![]() |
[76] |
Debela DT, Muzazu SG, Heraro KD, et al. (2021) New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med 9. https://doi.org/10.1177/20503121211034366 ![]() |
[77] |
Goldhirsch A, Winer EP, Coates AS, et al. (2013) Personalizing the treatment of women with early breast cancer: Highlights of the St gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol 24: 2206-2223. https://doi.org/10.1093/annonc/mdt303 ![]() |
[78] |
Shi J, Kantoff PW, Wooster R, et al. (2017) Cancer nanomedicine: Progress, challenges and opportunities. Nat Rev Cancer 17: 20-37. https://doi.org/10.1038/nrc.2016.108 ![]() |
[79] |
Bukowski K, Kciuk M, Kontek R (2020) Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci 21: 3233. https://doi.org/10.3390/ijms21093233 ![]() |
[80] |
Jing X, Yang F, Shao C, et al. (2019) Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer 18: 157. https://doi.org/10.1186/s12943-019-1089-9 ![]() |
[81] |
Yao Y, Zhou Y, Liu L, et al. (2020) Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci 7: 193. https://doi.org/10.3389/fmolb.2020.00193 ![]() |
[82] |
Sun T, Zhang YS, Pang B, et al. (2014) Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed 53: 12320-12364. https://doi.org/10.1002/anie.201403036 ![]() |
[83] |
Anjum S, Ishaque S, Fatima H, et al. (2021) Emerging applications of nanotechnology in healthcare systems: Grand challenges and perspectives. Pharmaceuticals 14: 707. https://doi.org/10.3390/ph14080707 ![]() |
[84] |
Moore ZS, Seward JF, Lane JM (2006) Smallpox. Lancet 367: 425-435. https://doi.org/10.1016/S0140-6736(06)68143-9 ![]() |
[85] |
Hoover HC, Surdyke MG, Dangel RB, et al. (1985) Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 55: 1236-1243. https://doi.org/10.1002/1097-0142(19850315)55:6<1236::aid-cncr2820550616>3.0.co;2-# ![]() |
[86] |
Miao L, Zhang Y, Huang L (2021) mRNA vaccine for cancer immunotherapy. Mol Cancer 20: 41. https://doi.org/10.1186/s12943-021-01335-5 ![]() |
[87] |
Saxena M, van der Burg SH, Melief CJM, et al. (2021) Therapeutic cancer vaccines. Nat Rev Cancer 21: 360-378. https://doi.org/10.1038/s41568-021-00346-0 ![]() |
[88] |
Le DT, Pardoll DM, Jaffee EM (2010) Cellular vaccine approaches. Cancer J 16: 304. https://doi.org/10.1097/PPO.0b013e3181eb33d7 ![]() |
[89] |
Farhood B, Najafi M, Mortezaee K (2019) CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol 234: 8509-8521. https://doi.org/10.1002/jcp.27782 ![]() |
[90] |
Fang RH, Hu CMJ, Luk BT, et al. (2014) Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett 14: 2181-2188. https://doi.org/10.1021/nl500618u ![]() |
[91] |
Yada K, Nogami K, Ogiwara K, et al. (2013) Activated prothrombin complex concentrate (APCC)-mediated activation of factor (F)VIII in mixtures of FVIII and APCC enhances hemostatic effectiveness. J Thromb Haemostasis 11: 902-910. https://doi.org/10.1111/jth.12197 ![]() |
[92] |
Kennedy R, Celis E (2008) Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 222: 129-144. https://doi.org/10.1111/j.1600-065X.2008.00616.x ![]() |
[93] | Rossella S, Trovato M, Manco R, et al. (2021) Exploiting viral sensing mediated by Toll-like receptors to design innovative vaccines. NPJ Vaccines 6. https://doi.org/10.1038/s41541-021-00391-8 |
[94] |
Asiry S, Kim G, Filippou PS, et al. (2021) The cancer cell dissemination machinery as an immunosuppressive niche: A new obstacle towards the era of cancer immunotherapy. Front Immunol 12. https://doi.org/10.3389/fimmu.2021.654877 ![]() |
[95] |
Ott PA, Hodi FS, Robert C (2013) CTLA-4 and PD-1/PD-L1 blockade: New immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19: 5300-5309. https://doi.org/10.1158/1078-0432.CCR-13-0143 ![]() |
[96] |
Hargrave A, Mustafa AS, Hanif A, et al. (2023) Recent advances in cancer immunotherapy with a focus on FDA-approved vaccines and neoantigen-based vaccines. Vaccines 11: 1633. https://doi.org/10.3390/vaccines11111633 ![]() |
[97] |
Osipov A, Murphy A, Zheng L (2019) Chapter two-from immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. Advances in Cancer Research. New York: Academic Press 63-144. https://doi.org/10.1016/bs.acr.2019.03.002 ![]() |
[98] |
Danila DC, Pantel K, Fleisher M, et al. (2011) Circulating tumors cells as biomarkers: Progress toward biomarker qualification. Cancer J 17: 438. https://doi.org/10.1097/PPO.0b013e31823e69ac ![]() |
[99] |
Rizzo A, Ricci AD, Brandi G (2021) PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer. Cancers 13: 558. https://doi.org/10.3390/cancers13030558 ![]() |
[100] |
Chae YK, Pan A, Davis AA, et al. (2016) Biomarkers for PD-1/PD-L1 blockade therapy in non–small-cell lung cancer: Is PD-L1 expression a good marker for patient selection?. Clin Lung Cancer 17: 350-361. https://doi.org/10.1016/j.cllc.2016.03.011 ![]() |
[101] |
Li K, Tian H (2019) Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. J Drug Targeting 27: 244-256. https://doi.org/10.1080/1061186X.2018.1440400 ![]() |
[102] |
Long J, Lin J, Wang A, et al. (2017) PD-1/PD-L blockade in gastrointestinal cancers: Lessons learned and the road toward precision immunotherapy. J Hematol Oncol 10: 146. https://doi.org/10.1186/s13045-017-0511-2 ![]() |
[103] |
Mas-Ponte D, McCullough M, Supek F (2022) Spectrum of DNA mismatch repair failures viewed through the lens of cancer genomics and implications for therapy. Clin Sc 136: 383-404. https://doi.org/10.1042/CS20210682 ![]() |
[104] |
Mardis ER (2019) Neoantigens and genome instability: Impact on immunogenomic phenotypes and immunotherapy response. Genome Med 11: 71. https://doi.org/10.1186/s13073-019-0684-0 ![]() |
[105] |
Shimozaki K, Hayashi H, Tanishima S, et al. (2021) Concordance analysis of microsatellite instability status between polymerase chain reaction based testing and next generation sequencing for solid tumors. Sci Rep 11: 20003. https://doi.org/10.1038/s41598-021-99364-z ![]() |
[106] |
Gomez-Martín C, Lopez-Rios F, Aparicio J, et al. (2014) A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond. Cancer Lett 351: 30-40. https://doi.org/10.1016/j.canlet.2014.05.019 ![]() |
[107] |
Duffy MJ, Crown J (2019) Biomarkers for predicting response to immunotherapy with immune checkpoint inhibitors in cancer patients. Clin Chem 65: 1228-1238. https://doi.org/10.1373/clinchem.2019.303644 ![]() |
[108] |
Riboldi M, Orecchia R, Baroni G (2012) Real-time tumour tracking in particle therapy: Technological developments and future perspectives. Lancet Oncol 13: e383-e391. https://doi.org/10.1016/S1470-2045(12)70243-7 ![]() |
[109] |
Danesi R, Fogli S, Indraccolo S, et al. (2021) Druggable targets meet oncogenic drivers: Opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards. ESMO Open 6: 100040. https://doi.org/10.1016/j.esmoop.2020.100040 ![]() |
[110] |
Sanchez A, Bocklage T (2019) Precision cytopathology: Expanding opportunities for biomarker testing in cytopathology. J Am Soc Cytopathol 8: 95-115. https://doi.org/10.1016/j.jasc.2018.12.003 ![]() |
[111] |
Łukaszewicz-Zając M, Pączek S, Muszyński P, et al. (2019) Comparison between clinical significance of serum CXCL-8 and classical tumor markers in oesophageal cancer (OC) patients. Clin Exp Med 19: 191-199. https://doi.org/10.1007/s10238-019-00548-9 ![]() |
[112] |
Roessler S, Jia HL, Budhu A, et al. (2010) A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 70: 10202-10212. https://doi.org/10.1158/0008-5472.CAN-10-2607 ![]() |
[113] |
Sun Z, Zhang N (2014) Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy. World J Surg Onc 12: 397. https://doi.org/10.1186/1477-7819-12-397 ![]() |
[114] |
Lakemeyer L, Sander S, Wittau M, et al. (2021) Diagnostic and prognostic value of CEA and CA19-9 in colorectal cancer. Diseases 9: 21. https://doi.org/10.3390/diseases9010021 ![]() |
[115] |
Jing JX, Wang Y, Xu XQ, et al. (2015) Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer. Asian Pac J Cancer Prev 15: 10267-10272. https://doi.org/10.7314/APJCP.2014.15.23.10267 ![]() |
[116] |
Galle PR, Foerster F, Kudo M, et al. (2019) Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int 39: 2214-2229. https://doi.org/10.1111/liv.14223 ![]() |
[117] |
He R, Yang Q, Dong X, et al. (2017) Clinicopathologic and prognostic characteristics of alpha-fetoprotein–producing gastric cancer. Oncotarget 8: 23817. https://doi.org/10.18632/oncotarget.15909 ![]() |
[118] |
Madhavan D, Peng C, Wallwiener M, et al. (2016) Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis. Carcinogenesis 37: 461-470. https://doi.org/10.1093/carcin/bgw008 ![]() |
[119] |
Hamam R, Hamam D, Alsaleh KA, et al. (2017) Circulating microRNAs in breast cancer: Novel diagnostic and prognostic biomarkers. Cell Death Dis 8: e3045-e3045. https://doi.org/10.1038/cddis.2017.440 ![]() |
[120] |
Li RY, Liang ZY (2020) Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response. Chin Med J 133: 2476-2485. https://doi.org/10.1097/CM9.0000000000001097 ![]() |
[121] |
Zhou H, Shen W, Zou H, et al. (2020) Circulating exosomal long non-coding RNA H19 as a potential novel diagnostic and prognostic biomarker for gastric cancer. J Int Med Res 48: 0300060520934297. https://doi.org/10.1177/0300060520934297 ![]() |
[122] |
Jiang L, Gu Y, Du Y, et al. (2019) Exosomes: Diagnostic biomarkers and therapeutic delivery vehicles for cancer. Mol Pharmaceutics 16: 3333-3349. https://doi.org/10.1021/acs.molpharmaceut.9b00409 ![]() |
[123] |
Huyghe N, Benidovskaya E, Stevens P, et al. (2022) Biomarkers of response and resistance to immunotherapy in microsatellite stable colorectal cancer: Toward a new personalized medicine. Cancers 14: 2241. https://doi.org/10.3390/cancers14092241 ![]() |
[124] |
Colle R, Cohen R, Cochereau D, et al. (2017) Immunotherapy and patients treated for cancer with microsatellite instability. Bull Cancer 104: 42-51. https://doi.org/10.1016/j.bulcan.2016.11.006 ![]() |
[125] |
He CY, Qiu MZ, Yang XH, et al. (2020) Classification of gastric cancer by EBV status combined with molecular profiling predicts patient prognosis. Clin Transl Med 10: 353-362. https://doi.org/10.1002/ctm2.32 ![]() |
[126] |
Shen H, Zhong M, Wang W, et al. (2017) EBV infection and MSI status significantly influence the clinical outcomes of gastric cancer patients. Clin Chim Acta 471: 216-221. https://doi.org/10.1016/j.cca.2017.06.006 ![]() |
[127] |
Yuan L, Xu ZY, Ruan SM, et al. (2020) Long non-coding RNAs towards precision medicine in gastric cancer: Early diagnosis, treatment, and drug resistance. Mol Cancer 19: 96. https://doi.org/10.1186/s12943-020-01219-0 ![]() |
[128] |
Cao F, Hu Y, Chen Z, et al. (2021) Circulating long noncoding RNAs as potential biomarkers for stomach cancer: A systematic review and meta-analysis. World J Surg Onc 19: 89. https://doi.org/10.1186/s12957-021-02194-6 ![]() |
[129] |
Li J, Wu Z, Lin R (2024) Impact of Helicobacter pylori on immunotherapy in gastric cancer. J Immunother Cancer 12: e010354. https://doi.org/10.1136/jitc-2024-010354 ![]() |
[130] | Zhong X, Zheng H, Zhao S, et al. (2024) Effects and mechanisms of Helicobacter pylori on cancers development and immunotherapy. Front Immunol 15. https://doi.org/10.3389/fimmu.2024.1469096 |
[131] |
Wang Y, Shatila M, Sperling G, et al. (2024) Helicobacter pylori infection and response of gastric cancer to immunotherapy. J Clin Oncol 42: 277-277. https://doi.org/10.1200/JCO.2024.42.3_suppl.277 ![]() |
[132] |
Magahis PT, Maron SB, Cowzer D, et al. (2023) Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors. J Immunother Cancer 11: e007699. https://doi.org/10.1136/jitc-2023-007699 ![]() |
[133] |
Hegde PS, Chen DS (2020) Top 10 challenges in cancer immunotherapy. Immunity 52: 17-35. https://doi.org/10.1016/j.immuni.2019.12.011 ![]() |
[134] |
Chen K, Shuen TWH, Chow PKH (2024) The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications. Br J Cancer 131: 420. https://doi.org/10.1038/s41416-024-02684-w ![]() |
[135] |
Chowell D, Morris LGT, Grigg CM, et al. (2018) Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 359: 582-587. https://doi.org/10.1126/science.aao4572 ![]() |
[136] |
Schneider BJ, Naidoo J, Santomasso BD, et al. (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39: 4073-4126. https://doi.org/10.1200/JCO.21.01440 ![]() |
[137] |
Gopalakrishnan V, Spencer CN, Nezi L, et al. (2018) Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science 359: 97-103. https://doi.org/10.1126/science.aan4236 ![]() |
[138] |
Pagliuca S, Gurnari C, Rubio MT, et al. (2022) Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond. Front Immunol 13. https://doi.org/10.3389/fimmu.2022.944872 ![]() |
[139] |
Mitchell AL, Gandhi A, Scott-Coombes D, et al. (2016) Management of thyroid cancer: United kingdom national multidisciplinary guidelines. J Laryngol Otol 130: S150-S160. https://doi.org/10.1017/S0022215116000578 ![]() |
[140] |
Dhatchinamoorthy K, Colbert JD, Rock KL (2021) Cancer Immune evasion through loss of MHC class I antigen presentation. Front Immunol 12: 636568. https://doi.org/10.3389/fimmu.2021.636568 ![]() |
[141] |
Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378: 158-168. https://doi.org/10.1056/NEJMra1703481 ![]() |
[142] |
Brahmer JR, Lacchetti C, Schneider BJ, et al. (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 36: 1714-1768. https://doi.org/10.1200/JCO.2017.77.6385 ![]() |
1. | Cheng-Cheng Zhu, Jiang Zhu, Dynamic analysis of a delayed COVID-19 epidemic with home quarantine in temporal-spatial heterogeneous via global exponential attractor method, 2021, 143, 09600779, 110546, 10.1016/j.chaos.2020.110546 | |
2. | Jinliang Wang, Ran Zhang, Toshikazu Kuniya, A reaction–diffusion Susceptible–Vaccinated–Infected–Recovered model in a spatially heterogeneous environment with Dirichlet boundary condition, 2021, 190, 03784754, 848, 10.1016/j.matcom.2021.06.020 | |
3. | Cheng-Cheng Zhu, Jiang Zhu, The effect of self-limiting on the prevention and control of the diffuse COVID-19 epidemic with delayed and temporal-spatial heterogeneous, 2021, 21, 1471-2334, 10.1186/s12879-021-06670-y | |
4. | Mohamed Mehdaoui, Abdesslem Lamrani Alaoui, Mouhcine Tilioua, Analysis of an optimal control problem for a spatio‐temporal SIR model with nonlinear density dependent diffusion terms, 2023, 0143-2087, 10.1002/oca.2976 | |
5. | Cheng-Cheng Zhu, Jiang Zhu, Spread trend of COVID-19 epidemic outbreak in China: using exponential attractor method in a spatial heterogeneous SEIQR model, 2020, 17, 1551-0018, 3062, 10.3934/mbe.2020174 | |
6. | Séverin Foko, Calvin Tadmon, Analysis of a delayed spatiotemporal model of HBV infection with logistic growth, 2024, 103, 0003-6811, 2283, 10.1080/00036811.2023.2291813 | |
7. | Yantao Luo, Yunqiang Yuan, Zhidong Teng, ANALYSIS OF A DEGENERATED DIFFUSION SVEQIRV EPIDEMIC MODEL WITH GENERAL INCIDENCE IN A SPACE HETEROGENEOUS ENVIRONMENT, 2024, 14, 2156-907X, 2704, 10.11948/20230346 | |
8. | Vasyl’ Davydovych, Vasyl’ Dutka, Roman Cherniha, Reaction–Diffusion Equations in Mathematical Models Arising in Epidemiology, 2023, 15, 2073-8994, 2025, 10.3390/sym15112025 | |
9. | Chang Zhai, Ping Chen, Zhuo Jin, Tak Kuen Siu, Epidemic modelling and actuarial applications for pandemic insurance: a case study of Victoria, Australia, 2024, 18, 1748-4995, 242, 10.1017/S1748499523000246 | |
10. | Cheng-Cheng Zhu, Jiang Zhu, Jie Shao, Epidemiological Investigation: Important Measures for the Prevention and Control of COVID-19 Epidemic in China, 2023, 11, 2227-7390, 3027, 10.3390/math11133027 | |
11. | Cheng-Cheng Zhu, Jiang Zhu, The existence conditions for global exponential attractor of non-autonomous evolution equations and applications, 2023, 173, 09600779, 113711, 10.1016/j.chaos.2023.113711 | |
12. | Pengfei Liu, Yantao Luo, Zhidong Teng, Role of media coverage in a SVEIR-I epidemic model with nonlinear incidence and spatial heterogeneous environment, 2023, 20, 1551-0018, 15641, 10.3934/mbe.2023698 | |
13. | Linhe Zhu, Yue Li, Le He, Shuling Shen, Pattern formation of network epidemic model and its application in oral medicine, 2025, 264, 01692607, 108688, 10.1016/j.cmpb.2025.108688 |
Parameter | Description |
S(x,t) | Density of susceptible individuals at location x and time t. |
V(x,t) | Density of vaccinated individuals at location x and time t. |
I(x,t) | Density of infected individuals at location x and time t. |
R(x,t) | Density of temporary restorers at location x and time t. |
Λ(x) | Total recruitment scale into this homogeneous social mixing community at location x. |
α(x) | Vaccination rate at location x. |
βi(x),i=1,2 | Effective transmission rate (average number of effective interactions per susceptible, vaccination individuals and infected individuals) at location x. |
ρ(x) | Relapse rate at location x. |
ϕ(x) | Per-capita recovery (treatment) rate at location x. |
μ(x) | Natural mortality rate at location x. |
ηi(x),i=1,2 | Disease-related death rate at location x. |
Parameter | Description | Data estimated | Data sources |
Λ | Recruitment scale of the population. | 300year−1 | [63] |
β1 | Estimated HBV prevalence (Transmission rate) without vaccination. | 0.062year−1 | [63] |
β2 | Estimated HBV prevalence (Transmission rate) with vaccination. | 0.035year−1 | [63] |
α | vaccinate rate. | 0.39year−1 | [63] |
ρ | Relapse rate. | 0.3year−1 | Estimate |
ϕ | The per-capita recovery (treatment) rate. | 0.08year−1 | Estimate |
μ | Natural mortality rate. | 0.1595year−1 | [64] |
η1 | The disease-related death rate of the HBV. | 0.2year−1 | [63] |
η2 | The disease-related death rate of being treated. | 0.1year−1 | Estimate |
dS | The diffusion coefficient of susceptible individuals. | 2year−1 | Estimate |
dV | The diffusion coefficient of vaccinated individuals. | 2.5year−1 | Estimate |
dI | The diffusion coefficient of infected individuals. | 1.5year−1 | Estimate |
dR | The diffusion coefficient of restored individuals. | 5year−1 | Estimate |
Parameter | Description |
S(x,t) | Density of susceptible individuals at location x and time t. |
V(x,t) | Density of vaccinated individuals at location x and time t. |
I(x,t) | Density of infected individuals at location x and time t. |
R(x,t) | Density of temporary restorers at location x and time t. |
Λ(x) | Total recruitment scale into this homogeneous social mixing community at location x. |
α(x) | Vaccination rate at location x. |
βi(x),i=1,2 | Effective transmission rate (average number of effective interactions per susceptible, vaccination individuals and infected individuals) at location x. |
ρ(x) | Relapse rate at location x. |
ϕ(x) | Per-capita recovery (treatment) rate at location x. |
μ(x) | Natural mortality rate at location x. |
ηi(x),i=1,2 | Disease-related death rate at location x. |
Parameter | Description | Data estimated | Data sources |
Λ | Recruitment scale of the population. | 300year−1 | [63] |
β1 | Estimated HBV prevalence (Transmission rate) without vaccination. | 0.062year−1 | [63] |
β2 | Estimated HBV prevalence (Transmission rate) with vaccination. | 0.035year−1 | [63] |
α | vaccinate rate. | 0.39year−1 | [63] |
ρ | Relapse rate. | 0.3year−1 | Estimate |
ϕ | The per-capita recovery (treatment) rate. | 0.08year−1 | Estimate |
μ | Natural mortality rate. | 0.1595year−1 | [64] |
η1 | The disease-related death rate of the HBV. | 0.2year−1 | [63] |
η2 | The disease-related death rate of being treated. | 0.1year−1 | Estimate |
dS | The diffusion coefficient of susceptible individuals. | 2year−1 | Estimate |
dV | The diffusion coefficient of vaccinated individuals. | 2.5year−1 | Estimate |
dI | The diffusion coefficient of infected individuals. | 1.5year−1 | Estimate |
dR | The diffusion coefficient of restored individuals. | 5year−1 | Estimate |